Participants will continue the mitapivat dose regimen that they were receiving at the final visit of their antecedent study.
The purpose of this study is to provide continued access to mitapivat for participants who completed an Agios-sponsored mitapivat study (antecedent) and do not have commercial access to mitapivat.